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Centres participating in the Arterial Revascularisation Trial (ART). Principal 
Investigators (shown in bold), co-investigators and co-ordinators (number of pa-
tients enrolled). 
 
1. John Radcliffe Hospital, Oxford, UK. D Taggart, C Ratnatunga, S Westaby, J 
Cook, C Wallis (427) 
2. Medical University of Silesia (2nd Department of Cardiac Surgery), Katowice, 
Poland. S Wos, M Jasinski, M Deja, K Widenka, A Blach, R Gocol, D 
Hudziak, P Zurek, R Bachowski, R Mrozek, T Kargul, W Domarardzki, J 
Frackiewicz (256) 
3. Edinburgh Royal Infirmary, Edinburgh, UK. V Zamvar, D Ezakadan (217) 
4. Austin and Repatriation Medical Centre, Melbourne, Australia. B Buxton, S 
Seevanayagam, G Matalanis, A Rosalion, J Negri, S Moten, V Atkinson, A 
Newcomb, P Polidano, R Pana, S Gerbo (192) 
5. University Hospital of Wales, Cardiff, UK, P O’Keefe, U von Oppell, D Me-
hta, A Azzu, A Szafranek, E Kulatilake, J Evans, N Martin, D Banner (185) 
6. Royal Sussex County, Brighton, UK. The late A Forsyth, U Trivedi, J Hyde, 
A Cohen, M Lewis, E Gardner, A MacKenzie, N Cooter, E Joyce, J Parker, F 
Champney (180) 
7. Freeman Hospital, Newcastle, UK. S Clark, J Dark, K Tocewicz, T Pillay, S 
Rowling, J Adams-Hall (152) 
8. Medical University of Silesia (1st Department of Cardiac Surgery), Katowice, 
Poland. A Bochenek, M Deja, M Cisowski, M Bolkowski, W Morawski, M 
Guc, M Krejca , M Wilczyn-ski, A Duralek, W Gerber, J Skarysz, R Shrestha, 
W Swiech, P Szmagala, L Krzych, A Pawlak, K Kepa (145) 
9. Royal Infirmary, Manchester, UK. R Hasan, D Keenan, B Prendergast, N 
Odom, K McLaugh-lin, G Cummings-Fosong, C Mathew, H Iles-Smith, A 
Oomen (115) 
10. King's College Hospital, London, UK. J Desai, A El-Gamel, L John, O 
Wendler, M Andrews, K Rance, R Williams, V Hogervorst, J Gregory, J 
Jessup, A Knighton, A Hoare (114) 
11. Royal Papworth Hospital, Cambridge, UK. A Ritchie, C Choong, S Nair, C 
Sudarshan, D Jenkins, S Large, M Barman, K Dhital, T Routledge, B 
Rosengard, H Munday, K Rintoul, E Jarrett, S Lao-Sirieix, A Wilkinson, L 
Garner, J Osmond, H Holcombe (101) 
12. Castle Hill Hospital, Hull, UK. A Cale, S Griffin, J Dickson, J Cook (97) 
13. Glenfield Hospital, Leicester, UK. T Spyt, A Gershlick, M Hickey, A Sos-
nowski, G Peek, J Szostek, L Hadjinikalaou,, E Logtens, M Oakley, S Leji 
(95) 
14. Harefield Hospital, London, UK. J Gaer, M Amrani, G Dreyfus, T Bahrami, 
F de Robertis, K Baig, G Asimakopoulos, H Vohra, V Pai, S Tadjkarimi, So-
leimani, G Stavri, G Bull, H Collappen (94) 
15. John Paul II, Krakow, Poland. J Sadowksi, B Kapelak, B Gaweda, P 
Rudzinski, J Stolinski, J Konstanty-Kalandyk, (92) 
16. Heart Institute of Pernambuco, Recife, Brazil. F Moraes, C Moraes, J Wan-
derley (82) 
17. Royal Brompton Hospital, London, UK. J Pepper, A De Souza, M Petrou, R 
Trimlett, T Morgan, J Gavino, SF Wang (82) 
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18. St George’s Hospital, London, UK. V Chandrasekaran, R Kanagasaby, M 
Sarsam, H Ryan, L Billings, L Ruddick, A Achampong, E Forster, E Mohama, 
P Mc Donnell (78) 
19. Medical University of Gdansk, Gdansk, Poland. R Pawlaczyk, P Siondalski, J 
Rogowski, K Roszak, K Jarmoszewicz, D Jagielak, S Gafka (74) 
20. Care Hospital, Hyderabad, India. G Mannam, L Rao Sajja, B Raju Dandu, G 
Naguboyina, A Yalla, J Peddireddy (69) 
21. Northern General Hospital, Sheffield, UK. N Briffa, P Braidley, G Cooper, A 
Knighton, K Al-len, G Sangha, C Bridge, H McMellon, P Shaw (67) 
22. Ospedale Mauriziano, Turin, Italy. R Casabona, G Actis Dato, G Bardi, S 
Del Ponte, Forsen-nati, F Parisi, G Punta, R Flocco, F Sansone, E Zingarelli, 
A Demartino (60) 
23. The Cardiothoracic Centre, Liverpool, UK. W Dihmis, M Kuduvali, C 
Prince, H Rogers, L McQuade, A Duran-Rosas (50) 
24. Szpital Uniwersytecki, Bydgoszcz, Poland. L Anisimowicz, M Bokszanski, W 
Pawliszak, J Kolakowski, G Lau, W Ogorzeja, I Gumanska, P Kulinski (23) 
25. Landesklinikum, St Polten and Center for Biomedical Research, Medical Uni-
versity of Vienna, Austria. B Podesser, K Trescher, O Bernecker, Ch Hol-
zinger, K Binder, I Schor, P Bergmann, H Kassal, E Dunkel (20) 
26. Escorts Heart Institute, New Delhi, India. N Trehan, Z Meharwal, R Mal-
hotra, M Goel, B Ku-mer, S Bazaz, N Bake, A Singh, Y Mishka, R Gupta, S 
Basumatary (19) 
27. Silesian Centre for Heart Disease, Zabrze, Poland. M Zembala, B Szafron, J 
Pacholewicz, M Krason, A Farmas, J Wojarski, B Zych, I Jaworska (10) 
28. Szpital Wojewodzki 2, Rzeszow, Poland. K Widenka, I Szymanik, M Kol-
wca, W Mazur, A Kurowicki, S Zurek, T Stacel, (6) 
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Trial Steering Committee 
 
1. Professor P Sleight, Emeritus Professor Cardiovascular Medicine, Oxford, UK 
(Chairman) 
2. The late Professor D Altman, Professor of Statistics in Medicine, Oxford, UK 
3. Professor K Channon, Professor of Cardiovascular Medicine, Oxford, UK 
4. Professor J Dark, Professor of Cardiac Surgery, Newcastle, UK 
5. Ms B Farrell, Trials Director, National Perinatal Epidemiology Unit, Oxford, 
6. Dr M Flather, Professor of Medicine and Clinical Trials, Norwich, UK 
7. Professor A Gray, Professor of Health Economics, Oxford, UK 
8. Professor J Pepper, Professor of Cardiac Surgery, London, UK 
9. Dr R Stables, Consultant Cardiologist, Liverpool, UK 
10. Professor D Taggart Consultant Cardiac Surgeon, Oxford, UK (Chief Investi-
gator) 
11. The late Professor G Vermes, Emeritus Professor of Hebrew Studies, Oxford, 
UK (Patient Lay Member) 
12. Professor J Pearson British Heart Foundation, London, UK (Observer) 
13. Dr M Pitman, Medical Research Council, London, UK (Observer) 
14. Mrs J Cook, Research Nurse, Oxford UK (Observer) 
15. Mrs C Wallis, Trial Administrator and Manager, Oxford UK (Observer) 
16. Dr B Lees, Trial Manager, Oxford UK (Observer) 
 
 
Data Monitoring Committee 
 
1. Professor S Yusuf, Professor of Medicine, Hamilton, Canada (Chairman) 
2. Professor S Pocock, Professor of Medical Statistics, London, UK 
3. Professor D Julian, Emeritus Professor of Cardiology, London, UK 
4. Professor T Treasure, Professor of Cardiothoracic Surgery, London, UK 
 
 
Clinical Event Adjudicators 
 
1. Mr U Trivedi, Royal Sussex County Hospital, Brighton, UK 
2. Mr P O'Keefe, University Hospital of Wales, Cardiff, UK 
3. Professor U Von Oppel, University Hospital of Wales, Cardiff, UK 
4. Mr V Zamvar, Edinburgh Royal Infirmary, Edinburgh, UK 
5. Mr A Cale, Castle Hill Hospital, Hull, UK 
6. Mr M Hickey, Glenfield Hospital, Leicester, UK 
7. Mr T Spyt, Glenfield Hospital, Leicester, UK 
8. Professor J Pepper, Royal Brompton Hospital, London, UK 
9. Mr R Kanagasabay, St. George's Hospital, London, UK 
10. Mr T Pillay, Freeman Hospital, Newcastle, UK 
11. Mr P Braidley, Northern General Hospital, Sheffield, UK 
12. Mr G Cooper, Northern General Hospital, Sheffield, UK 
13. Professor M Flather, University of East Anglia, Norwich, UK 
14. Dr J Collinson, Chelsea and Westminster Hospital, London, UK 
15. Dr A Bakhai, Barnet General Hospital, Barnet, UK 
16. Dr R Pawlaczyk, Medical University Of Gdansk, Gdansk, Poland 
17. Dr R O'Hanlon, Royal Brompton Hospital, London, UK 
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18. Dr D Kotecha, University of Birmingham, Birmingham UK 
19. Dr K Qureshi, London Chest Hospital, London, UK 
20. Professor L Krzych, Medical University Of Silesia, Katowice, Poland 
21. Professor T Geisler, University Hospital Tuebingen, Tuebingen, Germany 
22. Mr N Briffa, Northern General Hospital, Sheffield, UK 
23. Professor L Manzano-Espinosa, Hospital Universitario Ramon y Cajal Ma-
drid, Spain 
24. Professor M Jasinski, Department Cardiac and Thoracic Surgery, Wroclaw 
Medical University, Poland 
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Definitions of Outcome Events used in ART 
 
Adjudication method 
Two members of the clinical event review committee adjudicated each event (death, 
myocardial infarction, stroke and re-intervention) in a blinded fashion to ensure 
events met the pre-specified protocol definitions. If the two adjudicators did not con-
cur, then the event was adjudicated by a third adjudicator to reach resolution. All 
other adverse events requiring or prolonging hospitalisation were adjudicated by one 
member of the committee.   
 
1. Death 
 
(a) Death due to cardiac causes: 
Cardiac causes of death such as congestive heart failure, arrhythmia or myocardial in-
farction. 
(b) Other vascular causes of death: 
Vascular causes of death such as pulmonary embolus, dissection, cerebrovascular ac-
cident or bleeding event. 
(c) Non-cardiovascular causes of death: 
This includes any other cause of death. 
 
2. Major Bleed 
 
A major bleeding event is defined as requiring the use of blood products or a surgical 
procedure to deal with the bleed or its sequelae. 
 
3. Cerebrovascular Accident (CVA) 
 
A CVA is defined as a new focal neurological deficit thought to be vascular in origin 
with signs and symptoms lasting more than 24 hours. 
 
4. Revascularization 
 
For the purpose of the trial a revascularization is described as a Coronary Artery By-
pass Graft (CABG) or Percutaneous Coronary Intervention (PCI) after the trial proce-
dure. 
 
5. Myocardial Infarction (MI) 
 
(a) Non peri-procedural MI 
MI definition (2 out of the following 3 criteria must be present) 
• New onset or worsening pattern of characteristic ischemic chest pain occur-
ring at rest or with minimal exercise lasting longer than 20 minutes and requir-
ing nitrates or narcotic analgesia for relief of pain. 
• Elevation of cardiac markers (CK, CK-MB or Troponin) to at least twice the 
upper limit of the normal reference range (or greater than 20% of the previous 
value if already elevated in the context of early hospital MI).  
• ECG changes compatible with ischemia. 
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(b) MI within 48 hours of PTCA 
MI post-PTCA defined as: 
• the standard as above (at least 2 of 3 criteria)  
or  
• elevation of cardiac markers to at least 3 x the upper limit of normal.  
 
(c) MI within 72 hours of CABG 
MI post-CABG defined as: 
• elevation of cardiac markers to at least 5 x the upper limit of normal  
or 
• development of new pathological Q waves in at least two contiguous leads.  
 
Other Serious Adverse Events 
 
A “Serious Adverse Event” (SAE) is defined as requiring or prolonging hospital ad-
mission for medical reasons.  The hospitalization does not have to be related to the 
study procedure or patient’s underlying cardiovascular disease for it to constitute an 
“Other SAE”.   
 
Quality of Life 
Quality of life was assessed using the shortened World Health Organization Rose an-
gina questionnaire, the European Quality of Life–5 Dimensions (EQ-5D) question-
naire and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36).  
Quality of life data are reported separately.  
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Table S1: Additional baseline demographic and clinical characteristics by ran-
domized group 
 
 Bilateral graft 
group  
(n=1548) 
Single graft 
group 
(n=1554) 
Ethnic origin [n (%)]   
Caucasian 1418 (91.6%) 1431 (92.1%) 
East Asian 5 (0.3%) 1 (0.1%) 
South Asian 74 (4.8%) 76 (4.9%) 
Afro-Caribbean 0 2 (0.1%) 
African 4 (0.3%) 1 (0.1%) 
Other 47 (3.0%) 42 (2.7%) 
Missing 0 1 
NYHA class [n (%)]   
I 481 (31.1%) 481 (31.0%) 
II  722 (46.6%) 747 (48.1%) 
III 279 (18.0%) 263 (16.9%) 
IV 66 (4.3%) 61 (3.9%) 
Missing 0 2 
CCS class [n (%)]   
0  132 (8.5%) 128 (8.2%) 
I  348 (22.5%) 355 (22.8%) 
II  582 (37.6%) 598 (38.5%) 
III 368 (23.8%) 351 (22.6%) 
IV 118 (7.6%) 122 (7.9%) 
 
CCS = Canadian Cardiovascular Score.  NYHA = New York Heart Association;  
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Table S2: Details of surgical procedure, post-operative care and hospital stay 
 
Procedures Bilateral graft group Single graft group 
Details of operation  (n=1531) (n=1546) 
On pump 890 (58.1%) 928 (60.0%) 
Off pump  641 (41.9%) 618 (40.0%) 
Intra-operative conver-
sions to cardiopulmonary 
bypass  
15/641 (2.3%) 13/618 (2.1%) 
Mean (SD) duration of 
operation, mins 
Median (IQR) 
222 (61) 
 
215 (185 to 250) 
199 (58) 
 
190 (160 to 250) 
Number of vessels grafted  (n=1530) (n=1546) 
1 8 (0.5%) 11 (0.7%) 
2 272 (17.8%) 273 (17.7%) 
3 771 (50.4%) 749 (48.5%) 
4+ 479 (31.3%) 513 (33.2%) 
Radial artery graft 300 (19.4%) 339 (21.8%) 
Blood products used dur-
ing surgery 
  
Aprotinin started during 
surgery 
368/1531 (24.0%) 372/1545 (24.1%) 
Aprotinin given after sur-
gery 
98/1530 (6.4%) 89/1545 (5.8%) 
Blood transfusion 179/1492 (12.0%) 184/1515 (12.2%) 
Median (IQR) blood (red 
cells)  
500 (300 to 600) 500 (300 to 600) 
Platelets 46/1494 (3.1%) 35/1512 (2.3%) 
Fresh Frozen Plasma (FFP) 66/1493 (4.4%) 53/1513 (3.5%) 
Cell saver 461/1479 (31.2%) 474/1500 (31.6%) 
Immediate post-operative 
period  
  
Return to theatre and rea-
son 
66/1532 (4.3%) 54/1546 (3.5%) 
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Bleeding 51 44 
Tamponade 6 2 
Other 9 8 
Unknown 6 3 
Intra-aortic balloon pump 
used (IABP) 
68/1532 (4.4%) 57/1546 (3.7%) 
Renal support therapy 91/1532 (5.9%) 68/1545 (4.4%) 
 (n=1524) (n=1539) 
Mean (SD) Duration of 
ventilation (minutes) 
Median (IQR) 
968 (3029) 
 
598 (360 to 890) 
863 (3293) 
 
580 (335 to 830) 
Pre-discharge 
details 
(n=1429) (n=1447) 
ITU admissions: 0 8 (0.6%) 8 (0.6%) 
1 1362 (95.3%) 1390 (96.1%) 
2 or more 59 (4.1%) 49 (3.4%) 
 (n=1538) (n=1551) 
Mean (SD) ITU length of 
stay (hours) 
Median (IQR) 
41 (94) 
 
22 (15 to 45) 
38 (106) 
 
22 (16 to 43) 
Mean (SD) HDU length of 
stay (days) 
Median (IQR) 
2 (3.8) 
 
1 (1 to 2) 
2 (3.7) 
 
1 (1 to 2) 
Mean (SD) post-operative 
total hospital stay (days) 
Median (IQR) 
8.0 (7.4) 
 
6.5 (5 to 8) 
7.5 (7.6) 
 
6 (5 to 8) 
ITU = intensive therapy unit; HDU = high dependency unit, IQR = interquartile range 
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Table S3: Medications at 10 years 
Medication (%) 
Bilateral graft group 
(n=1075) 
Single graft group 
(n=1046) 
Aspirin 81.9% 80.1% 
Clopidogrel 13.7% 15.3% 
Warfarin 6.9% 6.3% 
Other anticoagulant 3.5% 4.4% 
Beta-blockers 71.8% 75.9% 
Calcium-channel antag-
onist 
21.4% 20.8% 
Nitrates 12.9% 11.9% 
Potassium channel acti-
vators 
4.1% 3.9% 
Statins 89.6% 91.2% 
Other lipid lowering 
agent 
1.4% 1.3% 
ACE inhibitor 56.3% 55.6% 
Angiotensin-II antago-
nist 
16.4% 16.7% 
Diuretics  19.6% 19.7% 
Digoxin 1.3% 2.2% 
Amiodarone 0.8% 0.9% 
Medication information is provided for those with complete case report form data at 10 
years.   
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Table S4: Classification of causes of death  
Cause of death 
n (%) 
Bilateral graft 
group 
(n=1548) 
Single graft group  
(n=1554) 
Subdistribution 
Hazard Ratio 
(95% CI) 
Cardiac 92 (5.9%) 91 (5.9%) 1.01 (0.76, 1.35) 
Non-cardiovascular 152 (9.8%) 160 (10.3%) 0.95 (0.76, 1.19) 
Other vascular 20 (1.3%) 28 (1.8%) 0.72 (0.40, 1.27) 
Unable to classify 51 (3.3%) 50 (3.2%) 1.02 (0.69, 1.51) 
Hazard ratios use the single graft group as the control. The widths of the confidence 
intervals have not been adjusted for multiplicity and should not be used for inference. 
 
 
 
Table S5: Per protocol analyses (comparison based on patients who actually re-
ceived randomly assigned treatment)  
 
Outcome Bilateral 
graft 
group  
n 
Single 
graft 
group 
n 
Deaths  
Bilateral 
graft group 
n (%) 
Deaths  
Single graft 
group 
n (%) 
Hazard Ratio 
(95% CI) 
Primary  
ITT unadjusted 
1548 1554 315 (20.3%) 329 (21.2%) 0.96 
(0.82, 1.12) 
Primary 
ITT adjusted1 
1548 1554 315 (20.3%) 329 (21.2%) 0.97 
(0.83, 1.14) 
Per protocol   
unadjusted 
1294 1494 255 (19.7%) 317 (21.2%) 0.92  
(0.78, 1.08) 
Per protocol   
adjusted1 
1294 1494 255 (19.7%) 317 (21.2%) 0.96 
(0.81, 1.13) 
 
Adjusted for age, gender, diabetes and ejection fraction1 
Hazard ratios use the single graft group as the control. The widths of the confidence 
intervals have not been adjusted for multiplicity and should not be used for inference. 
ITT= Intention to treat 
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Table S6: Baseline characteristics: as treated analysis of multiple (2 or more) 
arterial grafts versus single arterial graft 
 
 Multiple (2 
or more) ar-
terial grafts 
Single arterial 
graft 
  P 
n     1690     1330   
  Female n (%)     232 (13.7)       194 (14.6)   0.535  
  Age mean years (SD)   63.1 (8.9)      64.2 (8.9)  0.001  
Smoking (%)            0.007  
     Current smoker      257 (15.2)       170 (12.8)      
     Ex-smoker      908 (53.7)       790 (59.4)      
     Never smoked     525 (31.1)       370 (27.8)      
Ethnicity (%)            0.224  
    Caucasian    1552 (91.8)      1221 (91.9)      
    East Asian       5 (0.3)         0 (0.0)      
    South Asian      79 (4.7)        66 (5.0)      
    Afro-Caribbean       2 (0.1)         0 (0.0)      
    African       4 (0.2)         1 (0.1)      
    Other      48 (2.8)        41 (3.1)      
Height mean cm (SD)  170.6 (8.5)   169.9 (8.4)  0.020  
Weight mean kg (SD)   82.6 (13.8)    81.1 (13.9)  0.003  
Body Mass Index mean (SD)    28.4 (4.0)    28.0 (4.0)  0.035  
Systolic blood pressure mean mmHg 
(SD) 
 131.8 (18.2)   131.9 (18.3)  0.777  
Diastolic blood pressure mean mmHg 
(SD)  
  75.0 (11.2)    75.0 (10.9)  0.908  
Diabetes (%)            0.262  
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     No history     1285 (76.0)      1019 (76.6)      
     Insulin dependent diabetes     104 (6.2)        64 (4.8)      
     Non-insulin dependent diabetes     301 (17.8)       247 (18.6)      
Treated Hypertension n (%)    1293 (76.5)      1059 (79.6)   0.045  
Treated Hyperlipidemia n (%)    1583 (93.7)      1251 (94.1)   0.760  
Peripheral arterial disease n (%)     120 (7.1)        93 (7.0)   0.965  
Transient ischemic attack n (%)      51 (3.0)        56 (4.2)   0.096  
Cerebrovascular accident n (%)      50 (3.0)        39 (2.9)   1.000  
Myocardial infarction n (%)     672 (39.8)       589 (44.3)   0.015  
Percutaneous Coronary Intervention n 
(%) 
    258 (15.3)       217 (16.3)     
0.470  
New York Heart Association Class (%)            0.934  
      missing       1 (0.1)         1 (0.1)      
     I      517 (30.6)       422 (31.7)      
     II      814 (48.2)       619 (46.5)      
     III      290 (17.2)       234 (17.6)      
     IV       68 (4.0)        54 (4.1)      
Canadian Cardiovascular Society Class 
(%)  
          0.001  
     0      153 (9.1)       101 (7.6)      
     I      427 (25.3)       258 (19.4)      
     II      609 (36.0)       537 (40.4)      
     III      369 (21.8)       335 (25.2)      
     IV     132 (7.9)        99 (7.5)      
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Table S7: As treated analysis comparing multiple (2 or more) arterial grafts with 
single arterial graft: outcomes at 10 years  
 
  Multiple (2 or 
more)  
arterial grafts 
Single arterial 
graft 
Adjusted HR 
[95% CI] 
n  1690 1330   
All-cause death n (%) 315 (18.6) 307 (23.1) 0.81 [0.68-0.95] 
Myocardial Infarction n (%) 79 (4.7) 64 (4.8) 0.84 [0.59-1.19] 
Stroke n (%) 64 (3.8) 66 (5.0) 0.76 [0.53-1.11] 
Repeat revascularization n (%) 169 (10.0) 136 (10.2) 0.89 [0.70-1.14] 
All-cause death, myocardial in-
farction or stroke n (%) 
399 (23.6) 385 (28.9) 0.80 [0.69-0.93] 
The widths of the confidence intervals have not been adjusted for multiplicity and 
should not be used for inference. 
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Figure S1: Rates of  patients randomized to bilateral internal-thoracic-artery 
graft who actually received  single internal-thoracic-artery graft stratified by to-
tal number of cases performed by surgeon. The blue line represents regression 
line using polynomial spline function (information on participating surgeon was 
not available for 156 patients). 
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Figure S2 Panel A: As treated analysis of multiple (2 or more) arterial grafts ver-
sus single arterial graft (mortality). Adjusted HR 0.81; 95% CI 0.68-0.95 
 
 
 
Figure S2 Panel B: As treated analysis of multiple (2 or more) arterial grafts ver-
sus single arterial graft (all-cause mortality, myocardial infarction or stroke).  
Adjusted HR 0.80 95% CI 0.69-0.93 
 
 
 
